Cite
HARVARD Citation
Palich, R. et al. (2021). Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen. Journal of antimicrobial chemotherapy. pp. 477-481. [Online].